Table 6 Comparison of progression-free survival (months) after autologous stem cell transplantation calculated using Kaplan–Meier analysis and the groups with the log-rank test
n | Progression | Mean ± Standard Error (95% CI) | p | |
|---|---|---|---|---|
Progression-free survival times | 32 | 30 | 25.92 ± 3.66 (18.75–33.08) | N/A |
Age | ||||
< 60 | 20 | 18 | 28.87 ± 5.02 (19.04–38.70) | 0.238 |
≥ 60 | 12 | 12 | 21.08 ± 5.09 (11.11–31.06) | |
Sex | ||||
Male | 18 | 18 | 21.83 ± 4.79 (12.45–31.22) | 0.202 |
Female | 14 | 12 | 31.35 ± 5.68 (20.22–42.48) | |
Comorbidity | ||||
No | 16 | 16 | 24.13 ± 4.60 (15.11–33.14) | 0.401 |
Yes | 16 | 14 | 28.18 ± 5.91 (16.60–39.76) | |
Type | ||||
Heavy chain | 24 | 23 | 25.31 ± 4.71 (16.07–34.55) | 0.815 |
Light chain | 8 | 7 | 26.29 ± 2.71 (20.98–31.59) | |
Stage | ||||
Others | 10 | 10 | 29.00 ± 6.08 (17.08–40.92) | 0.642 |
Stage III (A/B) | 21 | 19 | 25.53 ± 4.71 (16.30–34.76) | |
Lytic lesion | ||||
No | 5 | 5 | 36.60 ± 10.91 (15.21–57.99) | 0.190 |
Yes | 16 | 15 | 23.75 ± 5.44 (13.09–34.42) | |
Plasmacytoma | ||||
No | 18 | 16 | 29.85 ± 5.35 (19.37–40.33) | 0.169 |
Yes | 14 | 14 | 21.00 ± 4.78 (11.63–30.38) | |
Hypercalcemia | ||||
No | 24 | 22 | 29.58 ± 4.54 (20.69–38.47) | 0.021 |
Yes | 5 | 5 | 11.40 ± 4.80 (1.99–20.81) | |
High creatinine (> 2) | ||||
No | 23 | 22 | 27.04 ± 4.14 (18.93–35.16) | 0.772 |
Yes | 9 | 8 | 22.83 ± 8.07 (7.01–38.66) | |
Bone marrow fibrosis level | ||||
0 | 6 | 6 | 22.17 ± 3.58 (15.15–29.19) | 0.479 |
1–4 | 25 | 23 | 26.32 ± 4.60 (17.31–35.33) |